Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor.
CD80
CD86
PD-L1
immunohistochemistry
lung cancer
Journal
Acta histochemica et cytochemica
ISSN: 0044-5991
Titre abrégé: Acta Histochem Cytochem
Pays: Japan
ID NLM: 0147110
Informations de publication
Date de publication:
26 Feb 2022
26 Feb 2022
Historique:
received:
03
09
2021
accepted:
10
12
2021
entrez:
21
4
2022
pubmed:
22
4
2022
medline:
22
4
2022
Statut:
ppublish
Résumé
It has been demonstrated that tumor cells express programed cell death protein 1 (PD-L1) to escape T lymphocytes that express programed cell protein 1 (PD-1), and PD-1/PD-L1 immune checkpoint inhibitors have been regarded in lung cancer patients. CD80 and CD86 are members of B7 superfamily which regulates T lymphocyte activation and tolerance. However, immunolocalization of CD80 and CD86 has not been examined in the lung carcinoma tissues and their clinical significance remains unknown. Therefore, to clarify clinical significance of CD80 and CD86, we immunolocalized these in 75 non-small cell lung carcinomas (NSCLC) in this study. Immunoreactivities of CD80 and CD86 were mainly detected in tumor-infiltrating macrophages. Immunohistochemical CD80 status was high in 56% of NSCLC, and it was positively associated with stage, pathological T factor, distant metastasis, histological type and PD-L1 status. Moreover, multivariate analysis turned out that the CD80 status was an independent worse prognostic factor. CD86 status was high in 53% of the cases, but it was not significantly associated with any clinicopathological parameters. These findings suggest that CD80 is a potent worse prognostic factor possibly in association with escape from immune attack in NSCLC.
Identifiants
pubmed: 35444349
doi: 10.1267/ahc.21-00075
pii: JST.JSTAGE/ahc/21-00075
pmc: PMC8913274
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25-35Informations de copyright
2022 The Japan Society of Histochemistry and Cytochemistry.
Déclaration de conflit d'intérêts
VThe authors declare that there are no conflicts of interest.
Références
Cell Physiol Biochem. 2018;47(2):721-734
pubmed: 29794465
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
J Immunol. 2008 Nov 15;181(10):6738-46
pubmed: 18981091
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Lung Cancer. 2017 Sep;18(5):572-582.e1
pubmed: 28318951
Front Oncol. 2021 Apr 29;11:672928
pubmed: 33996602
Immunity. 2007 Jul;27(1):111-22
pubmed: 17629517
J Thorac Oncol. 2015 Dec;10(12):1726-35
pubmed: 26473645
Oncotarget. 2014 Mar 30;5(6):1392-433
pubmed: 24722523
Semin Thorac Cardiovasc Surg. 2017 Autumn;29(3):408-415
pubmed: 29195578
Histol Histopathol. 2021 Oct;36(10):1053-1062
pubmed: 34296423
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Oncoimmunology. 2016 Mar 16;5(5):e1131379
pubmed: 27467949
J Thorac Oncol. 2021 Jul;16(7):1099-1117
pubmed: 33839365
Cancer Metastasis Rev. 2021 Sep;40(3):949-982
pubmed: 34236546
Lung Cancer. 2019 Oct;136:136-144
pubmed: 31499335
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Future Oncol. 2019 Feb;15(5):473-483
pubmed: 30628844
Cancer Treat Rev. 2014 Jul;40(6):716-22
pubmed: 24759599
Blood. 2018 Jan 4;131(1):58-67
pubmed: 29118008
Cancer Immunol Immunother. 1996 Dec;43(4):213-9
pubmed: 9003466
Breast Cancer. 2020 Sep;27(5):919-928
pubmed: 32314182
Cancer Med. 2019 Dec;8(17):7207-7218
pubmed: 31605439
Clin Lung Cancer. 2021 Jul;22(4):301-312.e8
pubmed: 33775558
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Br J Cancer. 2001 Nov 30;85(11):1731-7
pubmed: 11742495
Blood. 2013 Jan 31;121(5):734-44
pubmed: 23223433
J Cancer Res Clin Oncol. 1998;124(7):383-8
pubmed: 9719501
Front Oncol. 2021 Feb 24;10:618215
pubmed: 33718118
Mol Immunol. 2008 Aug;45(13):3567-72
pubmed: 18585785
Nat Immunol. 2013 Dec;14(12):1212-8
pubmed: 24240160
Semin Immunol. 2021 Feb;52:101480
pubmed: 34006473